FDA Approves Technegas® (Technetium Tc 99-m Labeled Carbon) Radioactive Diagnostic Agent
Cyclopharm Limited announced the company has received U.S. Food and Drug Administration (FDA) approval to commence commercial sales of Technegas® in the US market. The approval opens for Cyclopharm the single largest market for Technegas globally, and one which the company estimates to be initially worth approximately $180 million annually for the diagnosis and management of Pulmonary Embolism (PE).
• Strong pre-existing demand expected to drive sales momentum for an immediate US wide rollout.
• Approval allows for broad use of Technegas, supporting wider future indications across other
respiratory disease states including Chronic Obstructive Pulmonary Disease (COPD), Asthma, Long
COVID and lung cancer.
